These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6407165)

  • 1. [A randomized in vivo trial of 3 factor VIII preparations].
    Jacobsen L; Clausen C; Jans H; Gormsen J
    Ugeskr Laeger; 1983 Mar; 145(10):739-42. PubMed ID: 6407165
    [No Abstract]   [Full Text] [Related]  

  • 2. Factor VIII usage in the Wisconsin Hemophilia Program; factor VIII usage in hemophilia.
    Lange D; Lazerson J
    Wis Med J; 1982 Feb; 81(2):28-31. PubMed ID: 6803446
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical evaluation of a new factor VIII concentrate in hemophilic children].
    Carnelli V; Cultrera S; Simoni L; Pasqui G; Busso B; Bagnato L
    Pediatr Med Chir; 1983; 5(3):49-55. PubMed ID: 6417627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A clinical trial of a new Danish VIII preparation (intermediate purity type)].
    Ingerslev J; Christiansen SE; Riisom K; Wallevik K; Bernvil SS
    Ugeskr Laeger; 1984 Oct; 146(41):3101-3. PubMed ID: 6440331
    [No Abstract]   [Full Text] [Related]  

  • 5. The potent antihemophilic globulin concentrate derived from a cold insoluble fraction of human plasma: characterization and further data on preparation and clinical trial.
    Hershgold EJ; Pool JG; Pappenhagen AR
    J Lab Clin Med; 1966 Jan; 67(1):23-32. PubMed ID: 5321736
    [No Abstract]   [Full Text] [Related]  

  • 6. Prophylaxis in children with hemophilia: is it the optimal treatment?
    Lusher JM
    Thromb Haemost; 1997 Jul; 78(1):726-9. PubMed ID: 9198246
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of porcine factor VIII in Japan.
    Yoshioka A; Shima M; Morichika S; Terada S; Fukui H
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):26-8. PubMed ID: 7939769
    [No Abstract]   [Full Text] [Related]  

  • 8. Design of clinical studies with recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Pennington JE; Schwartz RS
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):27-8. PubMed ID: 1908123
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of porcine factor VIII in France.
    Negrier C
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):29-32. PubMed ID: 7939770
    [No Abstract]   [Full Text] [Related]  

  • 10. [Production of factor VIII preparations and their use in the substitution therapy of hemophilia A].
    Gaerisch F; Stein P
    Z Gesamte Inn Med; 1982 Oct; 37(19):641-4. PubMed ID: 6817530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rehabilitation of children and young people with hemophilia].
    Ahlberg A
    Lakartidningen; 1968 Mar; 65(10):1026-8. PubMed ID: 5720698
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of hemophilia complicated by inhibitors.
    Scand J Haematol Suppl; 1980; 35():135-64. PubMed ID: 6770458
    [No Abstract]   [Full Text] [Related]  

  • 13. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group.
    Kessler CM; Ludlam CA
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):22-7. PubMed ID: 8480193
    [No Abstract]   [Full Text] [Related]  

  • 14. Home management of hemophilia A.
    Van Eys J
    J Tenn Med Assoc; 1971 May; 64(5):407-10. PubMed ID: 5091669
    [No Abstract]   [Full Text] [Related]  

  • 15. [A clinical study of congenital factor XIII deficiency (author's transl)].
    Nakamura K; Itakura T; Yoshioka T; Suou T; Imai A
    Rinsho Ketsueki; 1977 May; 18(5):636-47. PubMed ID: 904084
    [No Abstract]   [Full Text] [Related]  

  • 16. In vivo characteristics of thaw siphon cryoprecipitate compared to other factor VIII preparations.
    Toolis F; McKay G; Prowse CV
    Thromb Haemost; 1980 Feb; 43(1):25-7. PubMed ID: 6773169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibitors suppression in hemophilia A with continued treatment of factor VIII].
    Aznar JA; Jiménez C; García I; Martín G; Borrego D; Peiro A; Marty ML
    Sangre (Barc); 1982; 27(4A):572. PubMed ID: 6818701
    [No Abstract]   [Full Text] [Related]  

  • 18. [The value of AHF-prophylaxis].
    Olin P
    Lakartidningen; 1968 Mar; 65(10):1031-2 passim. PubMed ID: 5720700
    [No Abstract]   [Full Text] [Related]  

  • 19. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
    Peerlinck K; Arnout J; Gilles JG; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1993 Feb; 69(2):115-8. PubMed ID: 8456422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of factor VIII in hemophilia A patients assessed by frequency response method.
    Durisová M; Dedík L; Bátorová A; Sakalová A; Hedera J
    Methods Find Exp Clin Pharmacol; 1998 Apr; 20(3):217-26. PubMed ID: 9646284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.